Upholding the Commitment to Quality Care and Clinical Innovation
Vision loss is a national public health concern that clearly worries most Americans. In a national poll on health attitudes, every major ethnic and racial group listed fear of vision loss among its top two health concerns. More than 70 percent of participants rated “loss of eyesight” as having the greatest impact on their quality of life. The economic impact of vision loss is also growing, with the total cost of vision loss expected to reach $373.2 billion a year by 2050, up from $145 billion in 2014.
Amid these challenging trends, Harvard Ophthalmology continues to forge a future without blindness. With landmark breakthroughs in anti-VEGF therapies, surgical and transplant techniques, ocular imaging, and laser surgery, the Department’s dedication to clinical innovation has led to many benchmarks in ophthalmic care, helping to define clinical excellence worldwide and bringing hope and healing to millions of people.
Committed to quality care, clinicians work tirelessly to provide excellent care to each and every patient as well as set international standards for quality and outcomes. Dedicated to assuring the safety and efficacy of these practices, the Quality Steering Committee at Mass. Eye and Ear leads a Department-wide effort to routinely evaluate clinical procedures and incidences, and publish their findings in a transparent, robust report for the public each year.